Daewoong showcases microneedle, biosimilar tech at CPHI Worldwide 2025

Daewoong Pharmaceutical said it participated in the world’s largest pharmaceutical exhibition, CPHI Worldwide 2025, held in Frankfurt, Germany, from Oct. 28 to 30, to highlight its next-generation drug delivery and biosimilar technologies as part of its global expansion strategy.

CPHI Worldwide is the world’s largest pharmaceutical trade exhibition, featuring more than 2,500 participating companies from over 150 countries and drawing around 40,000 attendees, including industry experts, investors, regulators, and business partners. The event includes exhibition booths, technology sessions, one-on-one business meetings, and seminars on the latest industrial and regulatory trends.

During the event, Daewoong introduced its flagship innovative drugs, including Fexuclue  (fexuprazan) and Envlo (enavogliflozin), alongside advanced formulation platforms such as GLP-1 microneedle patches and biosimilars, while pursuing new partnership and licensing opportunities.

Building on the success of last year’s CPHI 2024 in Milan, the company strengthened its global business network and collaboration initiatives.

According to Daewoong, one of the technologies that drew particular attention was its  microneedle patch-based drug delivery platform. Designed to replace subcutaneous injections, the patch offers key advantages such as reduced pain, easy self-administration, and improved patient compliance. The technology has recently shown significantly enhanced bioavailability, attracting strong interest from global partners.

The company is expanding the platform’s applications beyond semaglutide-based obesity treatments to growth hormone and botulinum toxin delivery, aiming to broaden its presence across diverse therapeutic areas through innovative formulation technologies.

Daewoong also emphasized its growing commitment to the biosimilar business as a next-generation growth driver.

The company is pursuing multiple models --  including independent global development, co-development, licensing, and CDMO collaborations -- in major markets such as the U.S. and Europe.

The recent appointment of Hong Seung-suh, a leading expert in the biosimilar field, as head of the Biosimilar Division is expected to further strengthen organizational capabilities. The company also plans to combine its proprietary formulation technologies with biosimilars to create differentiated biobetters.

Daewoong Bio, a subsidiary of Daewoong Pharmaceutical, jointly operated the booth to expand its global CDMO business and API exports. .

The company held meetings with 25 potential global CDMO clients, pursued export expansion worth approximately 17.4 billion won ($12 million) in API sales, and worked to diversify its raw material supply chain while strengthening R&D capabilities to boost global manufacturing competitiveness.

“Beyond showcasing our technologies, this year’s CPHI was a performance-driven event that allowed us to hold concrete business discussions with global partners,” Daewoong Pharmaceutical CEO Park Seong-soo said. “We will accelerate our entry into the global healthcare market with our microneedle-based formulation platforms and biosimilars as key future growth engines.”